|
|
Xifaxan (Rx) - Treatment for Travelers' Diarrhea
Salix's product, Xifaxan® (rifaximin), was approved by the U.S. Food and Drug Administration in May 2004. Xifaxan is a semi-synthetic, nonsystemic antibiotic. Xifaxan 200 mg tablets are indicated
for the treatment of patients (12 years of age and older) with travelers' diarrhea caused by noninvasive strains of Escherichia coli. Xifaxan is now approved in 20 countries and has been used for over
19 years in Italy with over 500 million tablets prescribed.
Please click a link below to be taken to that area
Xifaxan Physician Resource Center
US Pharmacists
Xifaxan® (rifaximin) Tablets are indicated for the treatment of patients (≥12 years of age) with travelers' diarrhea caused by non-invasive strains of
Escherichia coli. Xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. Xifaxan should be
discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered.
In clinical trials, Xifaxan was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1 %), rectal tenesmus 7.2%
(vs. 8.8%), defecation urgency 5.9% (vs. 9.2%) and nausea 5.3% (vs. 8.3%).
Consult with your physician to see if this product is right for you.
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email:
|
|